RGBP
Regen BioPharma, Inc.0.0084
-0.0016-16%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
463.97KP/E (TTM)
-Basic EPS (TTM)
-0.01Dividend Yield
0%Recent Filings
8-K
Issued 77.8M shares for debt
10-Q
Q1 FY2026 results
Regen Biopharma held net revenue steady at $59,065 for Q1 FY2026 ended December 31, 2025, matching y/y, yet ramped R&D to $210,000 from zero, driving operating loss to $551,624 (y/y +$490k) while net loss widened to $968k from $515k, largely from derivative expense swings. Cash drained to $4,578 amid $198k operating outflow, offset by $133k financing inflows; related-party notes payable fell to $133k with convertible notes at $947k net and $2.5M derivative liability. Issued 68M common shares for cash, debt, and awards tied to HemaXellerate Phase I planning. Shares outstanding ballooned. Cash is nearly gone.
8-K
Massive share issuance
Regen Biopharma issued 5 million shares on January 15, 2026, settling $11,449 principal and $8,101 interest on convertible debt; 5.3 million shares on January 29 for $13,000 debt; and 11.1 million shares on January 30 via Tier 2 Reg A for $50,000. Shares outstanding hit 129.5 million by February 2. Dilution mounts.
8-K
Stock dividend declared
Regen Biopharma's board declared a stock dividend on January 19, 2026, issuing one share of authorized but unissued Series A Preferred Stock per common, Series A, AA, M, or NC share held as of the February 3 record date, payable around February 9. This one-for-one distribution dilutes common equity while boosting preferred holdings. No cash impact disclosed.
10-K
FY2025 results
Regen Biopharma posted FY2025 net revenue of $236,561 from licensing deals with Zander Therapeutics and Oncology Pharma, flat year-over-year, while trimming operating loss to $338,540 from $417,221 via slashed R&D spend. Yet net loss ballooned to $1.3 million, hammered by $676K derivative expense and $158K interest. No quarterly breakdowns disclosed in the 10-K. Cash ticked up to $69,555 on $452K financing inflows, but $6.2M working capital deficit signals distress. No clinical trials advanced. Dependence on key personnel threatens momentum.
IPO
Employees
Sector
Industry
AURX
Nuo Therapeutics, Inc.
2.00-0.15
BCDA
BioCardia, Inc.
1.28-0.02
FBLG
FibroBiologics, Inc.
0.24-0.02
GBIO
Generation Bio Co.
5.38-0.01
IMA
ImageneBio, Inc.
6.25+0.08
REGN
Regeneron Pharmaceuticals, Inc.
746.36-6.26
RENB
Lunai Bioworks Inc.
1.42+0.00
RGNX
REGENXBIO Inc.
14.11+0.28
RMTG
Regenerative Medical Technology
0.04+0.00
XBIO
Xenetic Biosciences, Inc.
2.07-0.27